ResMed Inc. 10-Q Summary: Period Ended December 31, 1998
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep-disordered breathing, primarily obstructive sleep apnea. The report covers the three and six months ended December 31, 1998. Principal manufacturing operations are located in Australia, with distribution sites in the U.S., U.K., Asia, and Europe.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 1998 | Six Months Ended Dec 31, 1997 |
|---|---|---|
| Net Revenue | $40.7 million | $30.1 million |
| Gross Profit | $27.7 million | $19.5 million |
| Gross Margin | 68% | 65% |
| Net Income | $7.1 million | $4.4 million |
| Diluted EPS | $0.46 | $0.30 |
| Operating Cash Flow | $9.2 million | $1.3 million |
| Cash & Equivalents (End of Period) | $13.6 million | $7.6 million |
| Total Assets | $75.5 million | $57.0 million (approx) |
| Working Capital | $32.1 million | $32.8 million |
| Debt (Current Loan Payable) | $0.1 million | $0.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 35% year-over-year for the six-month period, driven by higher unit sales of flow generators and accessories, particularly in Latin and North America.
- Margin Expansion: Gross margin improved to 68% from 65%, attributed to a shift in sales mix toward higher-margin products, offsetting domestic price competition.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 37% due to an increase in sales personnel (from 124 to 185) and higher legal costs. R&D expenses increased 23% due to new product development.
- Capital Expenditures: Capital spending surged to $10.7 million (from $6.0 million) primarily for the construction of a new Australian manufacturing facility and production tooling.
- Foreign Exchange: Net foreign exchange losses decreased significantly compared to the prior year due to the company's hedging program.
Outlook, Risks, and Contingencies
- Liquidity: The company anticipates expending approximately $4.0 million over the next three months for the new facility, funded by operating cash flows. Total liquid assets (cash and marketable securities) stood at approximately $19.1 million.
- Legal Proceedings: Significant litigation exists with Respironics, Inc. regarding patent infringement in the U.S. and Australia. The company faces potential damages of approximately $1 million in Australia and ongoing legal costs. Market share in Australia has decreased following a patent revocation in 1994.
- Year 2000 Compliance: The company is implementing an Oracle Applications Enterprise package (estimated cost $2.0 million) to ensure Year 2000 compliance. Management expects total compliance costs to be approximately $100,000 beyond the system replacement. Failure to resolve Y2K issues with vendors or customers could materially affect operations.
- Accounting Changes: The company adopted SFAS No. 131 (Segment Reporting) and SFAS No. 130 (Comprehensive Income). The impact of SFAS No. 133 (Derivatives) has not yet been determined.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing patent litigation with Respironics, Inc.
- Confirm the timeline and budget adherence for the new Australian manufacturing facility construction.
- Monitor the effectiveness of foreign currency hedging strategies given the company's significant exposure to the Australian Dollar and European currencies.
- Review the progress of Year 2000 compliance for the company's supply chain and customer interface systems.
- Assess the sustainability of the 68% gross margin given the noted domestic price competition.